HCPCS Level II codes starting with Q

644 codes, page 1 of 7. Every code ever valid for billing is listed, including those now retired.

Code	Description	Status
Q0035	Cardiokymography	Valid
Q0081	Infusion therapy, using other than chemotherapeutic drugs, per visit	Valid
Q0083	Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit	Valid
Q0084	Chemotherapy administration by infusion technique only, per visit	Valid
Q0085	Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit	Valid
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	Valid
Q0092	Set-up portable x-ray equipment	Valid
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens	Valid
Q0112	All potassium hydroxide (koh) preparations	Valid
Q0113	Pinworm examinations	Valid
Q0114	Fern test	Valid
Q0115	Post-coital direct, qualitative examinations of vaginal or cervical mucous	Valid
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	Valid
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)	Valid
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 gram	Valid
Q0155	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0161	Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	Valid
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0166	Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen	Valid
Q0167	Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0169	Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0173	Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0174	Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen through FY2026	Terminated
Q0175	Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0177	Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0180	Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen	Valid
Q0181	Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	Valid
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg through FY2026	Terminated
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg through FY2026	Terminated
Q0222	Injection, bebtelovimab, 175 mg through FY2026	Terminated
Q0224	Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg	Valid
Q0234	Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg	Valid
Q0235	Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg	Valid
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Valid
Q0238	Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Valid
Q0239	Injection, bamlanivimab-xxxx, 700 mg through FY2026	Terminated
Q0240	Injection, casirivimab and imdevimab, 600 mg through FY2026	Terminated
Q0243	Injection, casirivimab and imdevimab, 2400 mg through FY2026	Terminated
Q0244	Injection, casirivimab and imdevimab, 1200 mg through FY2026	Terminated
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg through FY2026	Terminated
Q0247	Injection, sotrovimab, 500 mg through FY2026	Terminated
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg	Valid
Q0477	Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0478	Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type	Valid
Q0479	Power module for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0480	Driver for use with pneumatic ventricular assist device, replacement only	Valid
Q0481	Microprocessor control unit for use with electric ventricular assist device, replacement only	Valid
Q0482	Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only	Valid
Q0483	Monitor/display module for use with electric ventricular assist device, replacement only	Valid
Q0484	Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0485	Monitor control cable for use with electric ventricular assist device, replacement only	Valid
Q0486	Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only	Valid
Q0487	Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only	Valid
Q0488	Power pack base for use with electric ventricular assist device, replacement only	Valid
Q0489	Power pack base for use with electric/pneumatic ventricular assist device, replacement only	Valid
Q0490	Emergency power source for use with electric ventricular assist device, replacement only	Valid
Q0491	Emergency power source for use with electric/pneumatic ventricular assist device, replacement only	Valid
Q0492	Emergency power supply cable for use with electric ventricular assist device, replacement only	Valid
Q0493	Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only	Valid
Q0494	Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0495	Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0496	Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0497	Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0498	Holster for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0499	Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only	Valid
Q0500	Filters for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0501	Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0502	Mobility cart for pneumatic ventricular assist device, replacement only	Valid
Q0503	Battery for pneumatic ventricular assist device, replacement only, each	Valid
Q0504	Power adapter for pneumatic ventricular assist device, replacement only, vehicle type	Valid
Q0506	Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only	Valid
Q0507	Miscellaneous supply or accessory for use with an external ventricular assist device	Valid
Q0508	Miscellaneous supply or accessory for use with an implanted ventricular assist device	Valid
Q0509	Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a	Valid
Q0510	Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant	Valid
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	Valid
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	Valid
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	Valid
Q0514	Pharmacy dispensing fee for inhalation drug(s); per 90 days	Valid
Q0515	Injection, sermorelin acetate, 1 microgram	Valid
Q0516	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-days through FY2026	Terminated
Q0517	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days through FY2026	Terminated
Q0518	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days through FY2026	Terminated
Q0519	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days through FY2026	Terminated
Q0520	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days through FY2026	Terminated
Q0521	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription	Valid
Q1004	New technology intraocular lens category 4 as defined in federal register notice	Valid
Q1005	New technology intraocular lens category 5 as defined in federal register notice	Valid
Q2004	Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml	Valid
Q2009	Injection, fosphenytoin, 50 mg phenytoin equivalent	Valid
Q2017	Injection, teniposide, 50 mg through FY2026	Terminated
Q2026	Injection, radiesse, 0.1 ml	Valid
Q2028	Injection, sculptra, 0.5 mg	Valid
Q2034	Influenza virus vaccine, split virus, for intramuscular use (agriflu)	Valid
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)	Valid
Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)	Valid
Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)	Valid
Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)	Valid